APO Research
Talk to an analyst

APO RESEARCH · REPORT

Atypical Antipsychotic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Atypical Antipsychotic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchAtypical Antipsychotic Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Atypical Antipsychotic Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Atypical Antipsychotic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Atypical Antipsychotic Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Atypical Antipsychotic Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Atypical Antipsychotic Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Atypical Antipsychotic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Atypical Antipsychotic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Atypical Antipsychotic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Atypical Antipsychotic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Atypical Antipsychotic Drugs include Sun Pharmaceutical Industries, Johnson and Johnson, Qilu Pharmaceutical, Novartis AG, Eil Lilly and Company, Pfizer, GlaxoSmithKline, AstraZeneca and Sumitomo Dainippon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Atypical Antipsychotic Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Atypical Antipsychotic Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Atypical Antipsychotic Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Atypical Antipsychotic Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Atypical Antipsychotic Drugs Segment by Company

Sun Pharmaceutical Industries

Johnson and Johnson

Qilu Pharmaceutical

Novartis AG

Eil Lilly and Company

Pfizer

GlaxoSmithKline

AstraZeneca

Sumitomo Dainippon Pharma

Sanis Health

Cardinal Health

Bristol-Myers Squibb Company

Allergan

Atypical Antipsychotic Drugs Segment by Type

Olanzapine

Quetiapine

Risperidone

Ziprasidone

Others

Atypical Antipsychotic Drugs Segment by Application

Schizoaffective Disorder

Schizophrenia

Bipolar I Disorder

Major Depressive Disorder (MDD)

Atypical Antipsychotic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atypical Antipsychotic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Atypical Antipsychotic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atypical Antipsychotic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Atypical Antipsychotic Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Atypical Antipsychotic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Atypical Antipsychotic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Atypical Antipsychotic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Atypical Antipsychotic Drugs Industry Trends Table 2. Atypical Antipsychotic Drugs Industry Drivers Table 3. Atypical Antipsychotic Drugs Industry Opportunities and Challenges Table 4. Atypical Antipsychotic Drugs Industry Restraints Table 5. Global Atypical Antipsychotic Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Atypical Antipsychotic Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Atypical Antipsychotic Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Atypical Antipsychotic Drugs Sales Market Share by Manufacturers Table 9. Global Atypical Antipsychotic Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Atypical Antipsychotic Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Atypical Antipsychotic Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Atypical Antipsychotic Drugs Manufacturers, Product Type & Application Table 13. Global Atypical Antipsychotic Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Atypical Antipsychotic Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Olanzapine Table 17. Major Manufacturers of Quetiapine Table 18. Major Manufacturers of Risperidone Table 19. Major Manufacturers of Ziprasidone Table 20. Major Manufacturers of Others Table 21. Global Atypical Antipsychotic Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Atypical Antipsychotic Drugs Sales by Type (2021-2026) & (k units) Table 23. Global Atypical Antipsychotic Drugs Sales by Type (2027-2032) & (k units) Table 24. Global Atypical Antipsychotic Drugs Sales Market Share by Type (2021-2026) Table 25. Global Atypical Antipsychotic Drugs Sales Market Share by Type (2027-2032) Table 26. Global Atypical Antipsychotic Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Atypical Antipsychotic Drugs Revenue by Type (2021-2026) & (k units) Table 28. Global Atypical Antipsychotic Drugs Revenue by Type (2027-2032) & (k units) Table 29. Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Schizoaffective Disorder Table 32. Major Manufacturers of Schizophrenia Table 33. Major Manufacturers of Bipolar I Disorder Table 34. Major Manufacturers of Major Depressive Disorder (MDD) Table 35. Global Atypical Antipsychotic Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Atypical Antipsychotic Drugs Sales by Application (2021-2026) & (k units) Table 37. Global Atypical Antipsychotic Drugs Sales by Application (2027-2032) & (k units) Table 38. Global Atypical Antipsychotic Drugs Sales Market Share by Application (2021-2026) Table 39. Global Atypical Antipsychotic Drugs Sales Market Share by Application (2027-2032) Table 40. Global Atypical Antipsychotic Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Atypical Antipsychotic Drugs Revenue by Application (2021-2026) & (k units) Table 42. Global Atypical Antipsychotic Drugs Revenue by Application (2027-2032) & (k units) Table 43. Global Atypical Antipsychotic Drugs Revenue Market Share by Application (2021-2026) Table 44. Global Atypical Antipsychotic Drugs Revenue Market Share by Application (2027-2032) Table 45. Global Atypical Antipsychotic Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Atypical Antipsychotic Drugs Sales by Region (2021-2026) & (k units) Table 47. Global Atypical Antipsychotic Drugs Sales Market Share by Region (2021-2026) Table 48. Global Atypical Antipsychotic Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Atypical Antipsychotic Drugs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Atypical Antipsychotic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Atypical Antipsychotic Drugs Sales by Country (2021-2026) & (k units) Table 52. North America Atypical Antipsychotic Drugs Sales by Country (2027-2032) & (k units) Table 53. Europe Atypical Antipsychotic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Atypical Antipsychotic Drugs Sales by Country (2021-2026) & (k units) Table 55. Europe Atypical Antipsychotic Drugs Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Atypical Antipsychotic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Atypical Antipsychotic Drugs Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Atypical Antipsychotic Drugs Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Atypical Antipsychotic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Atypical Antipsychotic Drugs Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Atypical Antipsychotic Drugs Sales by Country (2027-2032) & (k units) Table 62. Global Atypical Antipsychotic Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Atypical Antipsychotic Drugs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Atypical Antipsychotic Drugs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Atypical Antipsychotic Drugs Revenue Market Share by Region (2021-2026) Table 66. Global Atypical Antipsychotic Drugs Revenue Market Share by Region (2027-2032) Table 67. Sun Pharmaceutical Industries Company Information Table 68. Sun Pharmaceutical Industries Business Overview Table 69. Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Product Portfolio Table 71. Sun Pharmaceutical Industries Recent Development Table 72. Johnson and Johnson Company Information Table 73. Johnson and Johnson Business Overview Table 74. Johnson and Johnson Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Johnson and Johnson Atypical Antipsychotic Drugs Product Portfolio Table 76. Johnson and Johnson Recent Development Table 77. Qilu Pharmaceutical Company Information Table 78. Qilu Pharmaceutical Business Overview Table 79. Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Qilu Pharmaceutical Atypical Antipsychotic Drugs Product Portfolio Table 81. Qilu Pharmaceutical Recent Development Table 82. Novartis AG Company Information Table 83. Novartis AG Business Overview Table 84. Novartis AG Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Novartis AG Atypical Antipsychotic Drugs Product Portfolio Table 86. Novartis AG Recent Development Table 87. Eil Lilly and Company Company Information Table 88. Eil Lilly and Company Business Overview Table 89. Eil Lilly and Company Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Eil Lilly and Company Atypical Antipsychotic Drugs Product Portfolio Table 91. Eil Lilly and Company Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Pfizer Atypical Antipsychotic Drugs Product Portfolio Table 96. Pfizer Recent Development Table 97. GlaxoSmithKline Company Information Table 98. GlaxoSmithKline Business Overview Table 99. GlaxoSmithKline Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. GlaxoSmithKline Atypical Antipsychotic Drugs Product Portfolio Table 101. GlaxoSmithKline Recent Development Table 102. AstraZeneca Company Information Table 103. AstraZeneca Business Overview Table 104. AstraZeneca Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. AstraZeneca Atypical Antipsychotic Drugs Product Portfolio Table 106. AstraZeneca Recent Development Table 107. Sumitomo Dainippon Pharma Company Information Table 108. Sumitomo Dainippon Pharma Business Overview Table 109. Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Product Portfolio Table 111. Sumitomo Dainippon Pharma Recent Development Table 112. Sanis Health Company Information Table 113. Sanis Health Business Overview Table 114. Sanis Health Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Sanis Health Atypical Antipsychotic Drugs Product Portfolio Table 116. Sanis Health Recent Development Table 117. Cardinal Health Company Information Table 118. Cardinal Health Business Overview Table 119. Cardinal Health Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Cardinal Health Atypical Antipsychotic Drugs Product Portfolio Table 121. Cardinal Health Recent Development Table 122. Bristol-Myers Squibb Company Company Information Table 123. Bristol-Myers Squibb Company Business Overview Table 124. Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Product Portfolio Table 126. Bristol-Myers Squibb Company Recent Development Table 127. Allergan Company Information Table 128. Allergan Business Overview Table 129. Allergan Atypical Antipsychotic Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Allergan Atypical Antipsychotic Drugs Product Portfolio Table 131. Allergan Recent Development Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Atypical Antipsychotic Drugs Distributors List Table 135. Atypical Antipsychotic Drugs Customers List Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Atypical Antipsychotic Drugs Product Image Figure 2. Global Atypical Antipsychotic Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Atypical Antipsychotic Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Atypical Antipsychotic Drugs Sales (2021-2032) & (k units) Figure 5. Global Atypical Antipsychotic Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Atypical Antipsychotic Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Olanzapine Image Figure 9. Quetiapine Image Figure 10. Risperidone Image Figure 11. Ziprasidone Image Figure 12. Others Image Figure 13. Global Atypical Antipsychotic Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Atypical Antipsychotic Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Atypical Antipsychotic Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Atypical Antipsychotic Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Atypical Antipsychotic Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2021-2032) Figure 19. Schizoaffective Disorder Image Figure 20. Schizophrenia Image Figure 21. Bipolar I Disorder Image Figure 22. Major Depressive Disorder (MDD) Image Figure 23. Global Atypical Antipsychotic Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Atypical Antipsychotic Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Atypical Antipsychotic Drugs Sales Market Share by Application (2021-2032) Figure 26. Global Atypical Antipsychotic Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Atypical Antipsychotic Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Atypical Antipsychotic Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Atypical Antipsychotic Drugs Sales Market Share by Country (2021-2032) Figure 31. U.S. Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Atypical Antipsychotic Drugs Sales Market Share by Country (2021-2032) Figure 36. Germany Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Atypical Antipsychotic Drugs Sales Market Share by Country (2021-2032) Figure 43. China Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Atypical Antipsychotic Drugs Sales Market Share by Country (2021-2032) Figure 51. Brazil Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Atypical Antipsychotic Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Atypical Antipsychotic Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Atypical Antipsychotic Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Atypical Antipsychotic Drugs Revenue (2021-2032) & (US$ Million) Figure 62. North America Atypical Antipsychotic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Atypical Antipsychotic Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Europe Atypical Antipsychotic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Atypical Antipsychotic Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Atypical Antipsychotic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Atypical Antipsychotic Drugs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Atypical Antipsychotic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Atypical Antipsychotic Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Atypical Antipsychotic Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Olanzapine
  • Quetiapine
  • Risperidone
  • Ziprasidone
  • Others
Applications
  • Schizoaffective Disorder
  • Schizophrenia
  • Bipolar I Disorder
  • Major Depressive Disorder (MDD)
Companies covered
  • Sun Pharmaceutical Industries
  • Johnson and Johnson
  • Qilu Pharmaceutical
  • Novartis AG
  • Eil Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Sumitomo Dainippon Pharma
  • Sanis Health
  • Cardinal Health
  • Bristol-Myers Squibb Company
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Atypical Antipsychotic Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Atypical Antipsychotic Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Atypical Antipsychotic Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Atypical Antipsychotic Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Atypical Antipsychotic Drugs Market Dynamics
  1. 2.1 Atypical Antipsychotic Drugs Industry Trends
  2. 2.2 Atypical Antipsychotic Drugs Industry Drivers
  3. 2.3 Atypical Antipsychotic Drugs Industry Opportunities and Challenges
  4. 2.4 Atypical Antipsychotic Drugs Industry Restraints
3 Atypical Antipsychotic Drugs Market by Manufacturers
  1. 3.1 Global Atypical Antipsychotic Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Atypical Antipsychotic Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Atypical Antipsychotic Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Atypical Antipsychotic Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Atypical Antipsychotic Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Atypical Antipsychotic Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Atypical Antipsychotic Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Atypical Antipsychotic Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Atypical Antipsychotic Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Atypical Antipsychotic Drugs Tier 1, Tier 2, and Tier 3
4 Atypical Antipsychotic Drugs Market by Type
  1. 4.1 Atypical Antipsychotic Drugs Type Introduction
  2. 4.1.1 Olanzapine
  3. 4.1.2 Quetiapine
  4. 4.1.3 Risperidone
  5. 4.1.4 Ziprasidone
  6. 4.1.5 Others
  7. 4.2 Global Atypical Antipsychotic Drugs Sales by Type
  8. 4.2.1 Global Atypical Antipsychotic Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Atypical Antipsychotic Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Atypical Antipsychotic Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Atypical Antipsychotic Drugs Revenue by Type
  12. 4.3.1 Global Atypical Antipsychotic Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Atypical Antipsychotic Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Atypical Antipsychotic Drugs Revenue Market Share by Type (2021-2032)
5 Atypical Antipsychotic Drugs Market by Application
  1. 5.1 Atypical Antipsychotic Drugs Application Introduction
  2. 5.1.1 Schizoaffective Disorder
  3. 5.1.2 Schizophrenia
  4. 5.1.3 Bipolar I Disorder
  5. 5.1.4 Major Depressive Disorder (MDD)
  6. 5.2 Global Atypical Antipsychotic Drugs Sales by Application
  7. 5.2.1 Global Atypical Antipsychotic Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Atypical Antipsychotic Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Atypical Antipsychotic Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Atypical Antipsychotic Drugs Revenue by Application
  11. 5.3.1 Global Atypical Antipsychotic Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Atypical Antipsychotic Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Atypical Antipsychotic Drugs Revenue Market Share by Application (2021-2032)
6 Global Atypical Antipsychotic Drugs Sales by Region
  1. 6.1 Global Atypical Antipsychotic Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Atypical Antipsychotic Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Atypical Antipsychotic Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Atypical Antipsychotic Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Atypical Antipsychotic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Atypical Antipsychotic Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Atypical Antipsychotic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Atypical Antipsychotic Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Atypical Antipsychotic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Atypical Antipsychotic Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Atypical Antipsychotic Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Atypical Antipsychotic Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Atypical Antipsychotic Drugs Revenue by Region
  1. 7.1 Global Atypical Antipsychotic Drugs Revenue by Region
  2. 7.1.1 Global Atypical Antipsychotic Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Atypical Antipsychotic Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Atypical Antipsychotic Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Atypical Antipsychotic Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Atypical Antipsychotic Drugs Revenue (2021-2032)
  8. 7.2.2 North America Atypical Antipsychotic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Atypical Antipsychotic Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Atypical Antipsychotic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Atypical Antipsychotic Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Atypical Antipsychotic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Atypical Antipsychotic Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Atypical Antipsychotic Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharmaceutical Industries
  2. 8.1.1 Sun Pharmaceutical Industries Company Information
  3. 8.1.2 Sun Pharmaceutical Industries Business Overview
  4. 8.1.3 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Product Portfolio
  6. 8.1.5 Sun Pharmaceutical Industries Recent Developments
  7. 8.2 Johnson and Johnson
  8. 8.2.1 Johnson and Johnson Company Information
  9. 8.2.2 Johnson and Johnson Business Overview
  10. 8.2.3 Johnson and Johnson Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson and Johnson Atypical Antipsychotic Drugs Product Portfolio
  12. 8.2.5 Johnson and Johnson Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Atypical Antipsychotic Drugs Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Novartis AG
  20. 8.4.1 Novartis AG Company Information
  21. 8.4.2 Novartis AG Business Overview
  22. 8.4.3 Novartis AG Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AG Atypical Antipsychotic Drugs Product Portfolio
  24. 8.4.5 Novartis AG Recent Developments
  25. 8.5 Eil Lilly and Company
  26. 8.5.1 Eil Lilly and Company Company Information
  27. 8.5.2 Eil Lilly and Company Business Overview
  28. 8.5.3 Eil Lilly and Company Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eil Lilly and Company Atypical Antipsychotic Drugs Product Portfolio
  30. 8.5.5 Eil Lilly and Company Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Atypical Antipsychotic Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Atypical Antipsychotic Drugs Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Atypical Antipsychotic Drugs Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Sumitomo Dainippon Pharma
  50. 8.9.1 Sumitomo Dainippon Pharma Company Information
  51. 8.9.2 Sumitomo Dainippon Pharma Business Overview
  52. 8.9.3 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Product Portfolio
  54. 8.9.5 Sumitomo Dainippon Pharma Recent Developments
  55. 8.10 Sanis Health
  56. 8.10.1 Sanis Health Company Information
  57. 8.10.2 Sanis Health Business Overview
  58. 8.10.3 Sanis Health Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanis Health Atypical Antipsychotic Drugs Product Portfolio
  60. 8.10.5 Sanis Health Recent Developments
  61. 8.11 Cardinal Health
  62. 8.11.1 Cardinal Health Company Information
  63. 8.11.2 Cardinal Health Business Overview
  64. 8.11.3 Cardinal Health Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Cardinal Health Atypical Antipsychotic Drugs Product Portfolio
  66. 8.11.5 Cardinal Health Recent Developments
  67. 8.12 Bristol-Myers Squibb Company
  68. 8.12.1 Bristol-Myers Squibb Company Company Information
  69. 8.12.2 Bristol-Myers Squibb Company Business Overview
  70. 8.12.3 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Product Portfolio
  72. 8.12.5 Bristol-Myers Squibb Company Recent Developments
  73. 8.13 Allergan
  74. 8.13.1 Allergan Company Information
  75. 8.13.2 Allergan Business Overview
  76. 8.13.3 Allergan Atypical Antipsychotic Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Allergan Atypical Antipsychotic Drugs Product Portfolio
  78. 8.13.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Atypical Antipsychotic Drugs Value Chain Analysis
  2. 9.1.1 Atypical Antipsychotic Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Atypical Antipsychotic Drugs Production Mode & Process
  6. 9.2 Atypical Antipsychotic Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Atypical Antipsychotic Drugs Distributors
  9. 9.2.3 Atypical Antipsychotic Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst